QEDDI – Queensland Emory Drug Discovery Initiative


QEDDI is a business unit of UniQuest.

Based at The University of Queensland’s Institute for Molecular Bioscience, and operational since 2016, QEDDI is the only facility of its kind in Australia: a world-class, fully integrated, drug discovery facility to accelerate the development of new drugs from leading academic research.

QEDDI has a commitment to address unmet needs across all human health, and aims to develop a project portfolio across several therapeutic areas.

Company details

Company Queensland Emory Drug Discovery Initiative

Service Biotechnology


QEDDI’s current projects, supported by its team of drug discovery experts, external collaborators and distinguished international advisory committee, seek to identify novel treatments for important diseases, including cancer, inflammatory disorders and neurodegenerative diseases.

QEDDI is supported by The University of Queensland, UniQuest, and the Queensland Government through the Advance Queensland initiative.

Our offering – a pipeline of novel therapeutic opportunities

QEDDI is The University of Queensland’s drug discovery and development capability, created to translate and accelerate innovative biological research from academia towards new medicines.

QEDDI has core capabilities and expertise in medicinal chemistry, compound screening and profiling.

QEDDI’s team, recruited from the biotech/pharma industry, is translating academic discoveries into drug candidates. Unique in Australia, QEDDI collaborates with academic researchers, providing an opportunity to advance biomedical research to new candidate therapeutics, enabling commercial partnerships to bring new medicines to the market. Its pipeline includes projects in the areas of CNS, inflammation and cancer.

Unique investment and licensing opportunities are available through UniQuest for QEDDI’s pipeline of novel therapeutic, validated and de-risked drug leads.